CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, ...

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

If you have been watching CRISPR Therapeutics (CRSP) lately, you have probably noticed the sharp rebound in its stock price. The rally was set off by compelling developments, specifically Casgevy’s ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Cathie Wood’s ARK ETFs have disclosed their daily trades for Wednesday, August 27th, 2025, with significant activity in the tech and biotech sectors. Leading the charge was a substantial investment in ...

Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...